{"id":"istradefylline-kw-6002","safety":{"commonSideEffects":[{"rate":null,"effect":"Dyskinesia"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Dizziness"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Insomnia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"By selectively antagonizing adenosine A2A receptors on GABAergic neurons in the striatum, istradefylline reduces inhibitory tone on motor output pathways. This potentiates dopamine signaling and improves motor symptoms in Parkinson's disease, particularly in patients experiencing motor fluctuations and \"off\" periods despite levodopa therapy.","oneSentence":"Istradefylline is an adenosine A2A receptor antagonist that blocks inhibitory signaling in the basal ganglia, thereby enhancing dopaminergic motor control.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:48:54.002Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Parkinson's disease with motor fluctuations in patients on levodopa therapy"}]},"trialDetails":[{"nctId":"NCT05377424","phase":"PHASE1, PHASE2","title":"Adenosine 2A Receptor Antagonism and AIH in ALS","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Florida","startDate":"2022-06-21","conditions":"ALS","enrollment":40},{"nctId":"NCT05217498","phase":"PHASE1, PHASE2","title":"Combining Low Oxygen Therapy and an Adenosine A2a Receptor Antagonist to Improve Functional Mobility After Spinal Cord Injury","status":"NOT_YET_RECRUITING","sponsor":"Randy Trumbower, PT, PhD","startDate":"2027-09-01","conditions":"Spinal Cord Injuries, Myelopathy","enrollment":40},{"nctId":"NCT05182151","phase":"","title":"Effect of Istradefylline Treatment on Behavioral Measures of Apathy in Parkinson's Disease.","status":"TERMINATED","sponsor":"Medical University of South Carolina","startDate":"2022-07-29","conditions":"Apathy, Parkinson Disease","enrollment":8},{"nctId":"NCT05333549","phase":"PHASE2","title":"Istradefylline for Parkinson Disease With Cognitive Impairment","status":"COMPLETED","sponsor":"Virginia Commonwealth University","startDate":"2022-07-18","conditions":"Parkinson Disease, Cognitive Impairment","enrollment":15},{"nctId":"NCT05885360","phase":"PHASE4","title":"Istradefylline Effect Protocol on Parkinson's Disease Tremor","status":"COMPLETED","sponsor":"Georgetown University","startDate":"2023-01-20","conditions":"Parkinson Disease, Tremor","enrollment":27},{"nctId":"NCT00199381","phase":"PHASE3","title":"An Extension of Istradefylline in North American Parkinson's Disease Patients Who Have Completed Study 6002-INT-001","status":"TERMINATED","sponsor":"Kyowa Kirin, Inc.","startDate":"2005-10","conditions":"Parkinson's Disease","enrollment":504},{"nctId":"NCT00456794","phase":"PHASE2","title":"12-Week, Double-Blind, Placebo-Controlled Study of 20 and 60 mg/Day Istradefylline in Parkinson's Disease Patients on Levodopa/Carbodopa","status":"COMPLETED","sponsor":"Kyowa Kirin, Inc.","startDate":"2002-03","conditions":"Parkinson's Disease","enrollment":325},{"nctId":"NCT00199420","phase":"PHASE3","title":"A Study of Istradefylline (KW-6002) in Treating Patients With Parkinson's Disease on Levodopa","status":"COMPLETED","sponsor":"Kyowa Kirin, Inc.","startDate":"2004-07","conditions":"Parkinson's Disease","enrollment":580},{"nctId":"NCT02610231","phase":"PHASE3","title":"Long Term Study of Istradefylline in Subjects With Moderate to Severe Parkinson's Disease","status":"COMPLETED","sponsor":"Kyowa Kirin Co., Ltd.","startDate":"2015-12","conditions":"Idiopathic Parkinson's Disease","enrollment":239},{"nctId":"NCT00199446","phase":"PHASE2","title":"Study of Istradefylline (KW-6002) for the Treatment of Restless Legs Syndrome","status":"COMPLETED","sponsor":"Kyowa Kirin, Inc.","startDate":"2005-07","conditions":"Sleep Disorder, Restless Legs Syndrome","enrollment":160},{"nctId":"NCT02609477","phase":"PHASE1","title":"A Study to Evaluate Abuse Potential of Istradefylline","status":"COMPLETED","sponsor":"Kyowa Kirin Co., Ltd.","startDate":"2016-01","conditions":"Drug Abuse","enrollment":42},{"nctId":"NCT00199368","phase":"PHASE3","title":"An Extension of Istradefylline in Parkinson's Disease Patients Who Have Completed Studies 6002-EU-007, 6002-US-013 or 6002-US-018","status":"COMPLETED","sponsor":"Kyowa Kirin, Inc.","startDate":"2004-10","conditions":"Parkinson's Disease","enrollment":1100},{"nctId":"NCT02174250","phase":"PHASE1","title":"The Effect of Rifampin on the Metabolism of Istradefylline in Healthy Volunteers.","status":"COMPLETED","sponsor":"Kyowa Kirin Co., Ltd.","startDate":"2014-06","conditions":"Parkinson's Disease","enrollment":20},{"nctId":"NCT02256033","phase":"PHASE1","title":"Effect of Mild Hepatic Impairment on the Pharmacokinetics of Istradefylline","status":"COMPLETED","sponsor":"Kyowa Kirin Co., Ltd.","startDate":"2014-08","conditions":"Hepatic Impairment","enrollment":20},{"nctId":"NCT00955045","phase":"PHASE2, PHASE3","title":"A Long-Term, Safety Study With a Flexible Dose Range of KW-6002 in Patients With Motor Response Complications on Levodopa/Carbidopa Therapy","status":"COMPLETED","sponsor":"Kyowa Kirin, Inc.","startDate":"2002-08","conditions":"Parkinson's Disease","enrollment":""},{"nctId":"NCT01968031","phase":"PHASE3","title":"A 12-week Randomized Study to Evaluate Oral Istradefylline in Subjects With Moderate to Severe Parkinson's Disease","status":"COMPLETED","sponsor":"Kyowa Kirin Co., Ltd.","startDate":"2013-10","conditions":"Idiopathic Parkinson's Disease","enrollment":613},{"nctId":"NCT00456586","phase":"PHASE2","title":"12-Week, Double-Blind, Placebo-Controlled, Randomized Study of the Efficacy of 40 mg/Day KW-6002 in Parkinson's Disease Patients on Levodopa/Carbidopa","status":"COMPLETED","sponsor":"Kyowa Kirin, Inc.","startDate":"2002-04","conditions":"Parkinson's Disease","enrollment":180},{"nctId":"NCT00199433","phase":"PHASE2","title":"A Study of Istradefylline (KW-6002) as Monotherapy in Parkinson's Disease (PD) Patients","status":"COMPLETED","sponsor":"Kyowa Kirin, Inc.","startDate":"2005-05","conditions":"Parkinson's Disease, Movement Disorder Syndrome","enrollment":160},{"nctId":"NCT00199394","phase":"PHASE3","title":"A Study of Istradefylline (KW-6002) for the Treatment of Parkinson's Disease","status":"COMPLETED","sponsor":"Kyowa Kirin Co., Ltd.","startDate":"2004-11","conditions":"Parkinson's Disease","enrollment":405},{"nctId":"NCT00199407","phase":"PHASE3","title":"A Study of Istradefylline (KW-6002) for the Treatment of Parkinson's Disease in Patients Taking Levodopa","status":"COMPLETED","sponsor":"Kyowa Kirin, Inc.","startDate":"2004-06","conditions":"Parkinson's Disease","enrollment":230},{"nctId":"NCT00199355","phase":"PHASE2","title":"A Study of Istradefylline (KW-6002) for the Treatment of Parkinson's Disease in Patients Taking Levodopa","status":"COMPLETED","sponsor":"Kyowa Kirin Co., Ltd.","startDate":"2005-04","conditions":"Parkinson's Disease","enrollment":75},{"nctId":"NCT00203957","phase":"PHASE3","title":"Study of KW-6002 (Istradefylline) in Parkinson's Disease in Patients With Motor Response Complications on Levodopa","status":"COMPLETED","sponsor":"University of Chicago","startDate":"2005-03","conditions":"Parkinson's Disease","enrollment":10},{"nctId":"NCT00957203","phase":"PHASE3","title":"Long-Term Safety Study of KW-6002 (Istradefylline) in Parkinson's Disease Patients","status":"COMPLETED","sponsor":"Kyowa Kirin Co., Ltd.","startDate":"2009-10","conditions":"Parkinson's Disease","enrollment":308},{"nctId":"NCT00955526","phase":"PHASE3","title":"Study of KW-6002 (Istradefylline) for the Treatment of Parkinson's Disease in Patients Taking Levodopa","status":"COMPLETED","sponsor":"Kyowa Kirin Co., Ltd.","startDate":"2009-07","conditions":"Parkinson's Disease","enrollment":373},{"nctId":"NCT00455507","phase":"PHASE2","title":"A Phase 2b Study of Istradefylline (KW-6002) for the Treatment of Parkinson's Disease in Patients Taking Levodopa","status":"COMPLETED","sponsor":"Kyowa Kirin Co., Ltd.","startDate":"2007-03","conditions":"Parkinson's Disease","enrollment":363},{"nctId":"NCT00250393","phase":"PHASE2","title":"A Study of Istradefylline (KW-6002) for the Treatment of Parkinson's Disease","status":"COMPLETED","sponsor":"Kyowa Kirin Co., Ltd.","startDate":"2005-11","conditions":"Parkinson's Disease","enrollment":64},{"nctId":"NCT00006337","phase":"PHASE2","title":"KW-6002 to Treat Parkinson's Disease","status":"COMPLETED","sponsor":"National Institute of Neurological Disorders and Stroke (NINDS)","startDate":"2000-10","conditions":"Parkinson's Disease","enrollment":16}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":67,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Istradefylline (KW-6002)","genericName":"Istradefylline (KW-6002)","companyName":"Kyowa Kirin, Inc.","companyId":"kyowa-kirin-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Istradefylline is an adenosine A2A receptor antagonist that blocks inhibitory signaling in the basal ganglia, thereby enhancing dopaminergic motor control. Used for Parkinson's disease with motor fluctuations in patients on levodopa therapy.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}